Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guoliang Shao

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Frontiers in Immunology|November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trialQian Qiao, Chun Han, Sisi Ye, et al.
BMC Cancer|March 4, 2018
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON studySheng-Long Ye, Jiamei Yang, Ping Bie, et al.
Eclinicalmedicine|October 17, 2022
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind studyGuoliang Shao, Yuxian Bai, Xianglin Yuan, et al.
BMC Cancer|December 8, 2020
Cancer patient management strategy in a Cancer Center of Zhejiang, China during the COVID-19 pandemicSongxiao Xu, Xiangdong Cheng, Zhiwen Pan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 24, 2024
A Transformer-Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablationWentao Wang, Yueyue Wang, Danjun Song, et al.
Liver Cancer|June 16, 2023
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular CarcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
Oncotarget|January 7, 2016
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON studySheng-Long Ye, Xiaoping Chen, Jiamei Yang, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II TrialJianming Xu, Jie Shen, Shanzhi Gu, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Frontiers in Immunology|November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trialQian Qiao, Chun Han, Sisi Ye, et al.
BMC Cancer|March 4, 2018
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON studySheng-Long Ye, Jiamei Yang, Ping Bie, et al.
Eclinicalmedicine|October 17, 2022
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind studyGuoliang Shao, Yuxian Bai, Xianglin Yuan, et al.
BMC Cancer|December 8, 2020
Cancer patient management strategy in a Cancer Center of Zhejiang, China during the COVID-19 pandemicSongxiao Xu, Xiangdong Cheng, Zhiwen Pan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 24, 2024
A Transformer-Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablationWentao Wang, Yueyue Wang, Danjun Song, et al.
Liver Cancer|June 16, 2023
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular CarcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
Oncotarget|January 7, 2016
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON studySheng-Long Ye, Xiaoping Chen, Jiamei Yang, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II TrialJianming Xu, Jie Shen, Shanzhi Gu, et al.
Pageof 9